As competition in ileal bile acid transporter inhibitors is expected to increase,a review of the landscape of ultra-orphan pediatric cholestasis diseases suggests Albireo Pharma's odevixibat remains the leader in the category, William Blair analyst Tim Lugo tells investors in a research note. Albireo's IBAT inhibitor odevixibat is currently in a single registrational Phase III PEDFIC-1 study in progressive familial intrahepatic cholestasis, with top-line data readout expected midyear 2020, adds the analyst. He continues to view the ultra-orphan pediatric cholestatic diseases as blockbuster ultra-orphan markets and keeps an Outperform rating on Albireo.